Breast & Ovarian Cancer: Screening Disparities & Solutions
Black women experience disproportionately late-stage diagnoses of breast cancer and ovarian cancer,according to a new report. This stark reality highlights critical racial disparities in healthcare, emphasizing the urgent need for improved screening and equitable access to care. Experts, like Dr. CK Wang, stress the importance of timely screenings, especially for breast cancer, where mammography guidelines exist. However, with the lack of effective early detection methods for ovarian cancer, diagnosis often comes too late. Addressing these disparities demands not only more research and funding, but also a focus on including underrepresented populations in clinical trials.News Directory 3 is committed to covering these vital issues. discover what’s next in the fight for equitable cancer care, including advancements in therapies and screening methods.
Report: Black Women Face Disparities in Breast Cancer and Ovarian Cancer Diagnoses
Updated June 01, 2025
Black women are more likely to be diagnosed with advanced-stage breast cancer and ovarian cancer than White women, according to a recent report. the data underscores existing racial disparities in cancer diagnosis and treatment, highlighting the urgent need for improved screening and access to care.
Dr. CK Wang,chief medical officer at COTA,emphasized the importance of timely screenings,particularly for breast cancer,where mammography guidelines exist but vary based on age and risk factors. For ovarian cancer, though, Wang noted the absence of effective screening tools frequently enough leads to diagnoses at later stages.
The lack of screening methods means diagnosis often relies on a clinician recognizing vague abdominal symptoms, such as discomfort or bloating. Wang stressed the need for clinicians to administer the appropriate tests promptly to detect the disease earlier.
It is incumbent upon the clinician,whichever clinician that is that the patient is seeing,to hopefully do the right test and hopefully be able to pick up the disease much earlier on than it is typical.
Wang also pointed out that ovarian cancer research is underfunded, which has historically limited therapeutic advancements.However, he expressed optimism about recent drug and therapy developments and hopes this trend continues.
He further emphasized the importance of including underrepresented populations in clinical trials to better understand their care experiences and ensure they align with established standards.Wang believes these patients comprise a meaningful portion of the overall population.
What’s next
Future efforts should focus on improving screening methods for ovarian cancer, increasing funding for research, and ensuring equitable access to care for all women, particularly those in underrepresented communities, to address these disparities in cancer diagnosis and outcomes.